Keywords: Tumors (Pre-Treatment), Data Analysis
Motivation: Improving glioblastoma outcomes is hindered by our limited understanding of its metabolic profile, which impedes targeted therapy development.
Goal(s): This study aims to develop a robust pipeline using deuterium metabolic imaging (DMI) to investigate glioblastoma metabolism.
Approach: Glioblastoma patients underwent 3T structural imaging and 7T DMI. The resulting data was segmented, co-registered, and processed for regional analysis to extract and quantify metabolite concentrations and flux.
Results: The pipeline successfully extracted metabolite concentrations in tumour and contralateral control tissue, demonstrating its potential in analysing metabolic changes in glioblastoma, paving the way for further clinical study.
Impact: This study establishes methods for ultra-high field deuterium metabolic imaging (7T DMI) to probe glioblastoma metabolism, enabling precise monitoring of metabolic changes. This may enable research to improve therapeutic outcomes, for example by allowing personalised treatment approaches.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords